• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Employment of Higher Doses of Botulinum Toxin Type A to Reduce Spasticity After Stroke
Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity with efficacy, reversibility, and low prevalence of complications. Current guidelines suggest a dose up to 600 units (U) of onabotulinumtoxinA/incobotulinumtoxinA or up to 1500 U of abobotulinumtoxinA to treat post-stroke spasticity to avoid important adverse effects. However, recently, higher doses of botulinum toxin type A were employed, especially in case of upper and lower limb severe spasticity.
Source: Journal of the Neurological Sciences - February 5, 2015 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Maurizio Ranieri, Giovanni Valeno, Antonio Albano, Alessio Baricich, Carlo Cisari, Domenico Intiso, Alberto Pilotto, Giancarlo Logroscino, Francesco Panza Source Type: research

Employment status, social function decline and caregiver burden among stroke survivors. A South Indian study
Conclusions: Loss of occupation among stroke survivors is high. The decline in social function among stroke survivors and caregivers was significant. Even though functional disability contributed to employment loss and social function decline among stroke survivors, it did not have a significant impact on caregiver burden.
Source: Journal of the Neurological Sciences - July 29, 2013 Category: Neurology Authors: Sapna Erat Sreedharan, J.P. Unnikrishnan, M.G. Amal, B.S. Shibi, Sankara Sarma, P.N. Sylaja Tags: Original Articles Source Type: research